Zheng Feng
Director / Head of Clinical Genomics EMD Serono, An affiliate of Merck KGaA, Darmstadt, Germany
Seminars
Thursday 25th September 2025
Panel Discussion: Paving Towards Strategic Drug-Diagnostic Market Entry in China – From Trial Design to Commercial Success
9:00 am
- Which potential challenges in trial design are we aware of?
- Which CDx strategy and testing models are optimal for maximizing market patient access in China?
- What are the CDx policies and regulations across China, and how can we address critical bottlenecks regarding regulatory adherence and commercialization?
- What precision medicine marker developments are currently underway which might change the future testing paradigm? How might this inform vendor selection?
Tuesday 23rd September 2025
Panel Discussion: Improving Patient Monitoring through Innovations in Liquid Biopsy Analysis
3:30 pm
- Discussing innovations in liquid for early cancer detection and monitoring
- How to integrate liquid biopsy derived markers into clinical trial designs
- How can we build successful liquid biopsy collaborations to pioneer future trial design?
- What are the key FDA regulatory requirements for liquid biopsy assays, and how do they differ for companion diagnostics versus standalone tests?
Tuesday 23rd September 2025
Clinical Applications of Liquid Biopsy in Advancing Precision Oncology-Driven Drug Development: Current Trends & Future Directions
2:40 pm
- Overview of ctDNA applications in clinical drug development with a focus on adjuvant settings and mechanism of tumor shedding
- Developing a fit-for-purpose liquid biopsy strategy
- Navigating future directions by balancing novel technologies with clinical application realities
- Looking ahead: AI and GPT-current status and future implications
